Gilde Healthcare

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

Moin Saleem(Co-founder & Chief Scientific Advisor)

Co-investorsSofinnova PartnersForbionBritish Patient Capital

Vesper Medical develops a modular venous stent portfolio designed to address the anatomical challenges of the iliac and femoral veins for treating deep venous disease.

HealthtechMedical DevicesWayne, US

Bruce J. Shook(President and CEO)Monica Klos(Executive Officer)Neil Hattangadi(Director)Peter Schneider(Director)Mark Garcia(Director)Dennis W. Wahr(Director)

Co-investorsNew Enterprise Associates (NEA)Lightstone VenturesVensana Capital415 Capital

VS3 Medical is a medical device company developing the VS3 Medical Stent System, an investigational neurovascular implant designed to treat symptomatic venous sinus stenosis within the dural venous sinus anatomy.

HardwareHealthtechMedical Devices

Co-investorsAPERTURE Venture PartnersUS Venture Partners

HealthtechWakefield, US

Tim A. Fischell(Executive Officer, Director)Kate Rumrill(Executive Officer, Director)Lisa Mastromattei(Executive Officer)Ronald D Bache(Executive Officer, Director)Vartan E. Ghazarossian(Executive Officer, Director)Vartan Ghazarossian(Executive Officer)

Co-investorsMichigan Capital NetworkBioStar VenturesMAF

Eagle Pharmaceuticals develops and commercializes specialty pharmaceutical products for acute care and oncology, including injectable medications for procedural sedation, chemotherapy, lymphomas, and malignant hyperthermia management.

BiotechHealthtechMedical DevicesIndianapolis, US

Co-investorsF-Prime Capital

Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).

BiotechHealthtechMedical DevicesAustin, US

Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)

BoardGeoff Pardo(Director)

Co-investorsBroadview VenturesRiverVest Venture PartnersTMC Venture FundCadence Healthcare VenturesGilmartin Capital LLCS3 Ventures+1 more

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)

Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundForbion+1 more

Elmsford, US

Jonathan Taqqu(Executive Officer, Director)

BoardJohn Lee(Director)

Co-investorsHealthy Ventures.406 VenturesAlleyCorpCVS Health VenturesSandbox Clinical Ventures

GammaTile Therapy, a surgically targeted radiation therapy for operable brain tumors

HealthtechTempe, US

David G. Brachman(Executive Officer, Director)Per Langoe(Executive Officer, Director)James Leech(Executive Officer)Matthew E. Likens(Executive Officer, Director)

BoardGeoff Pardo(Director)inPrattipati Laxminarain(Director)

Co-investorsAccelmed PartnersFemHealth VenturesBlueStone Venture PartnersEvidity Health CapitalMedical Technology Venture PartnersMedTech Venture Partners+2 more

Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.

HardwareHealthtechMedical DevicesIrvine, US

William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)

BoardDonald Milder(Director)Kirk Nielsen(Director)inJonathan Root(Director)inBrian Cox(Director)

Co-investorsUS Venture PartnersVensana CapitalVersant Ventures

LUMICKS develops life science research tools that measure and apply forces around biological interactions to link structural and 'omics analysis to functional outcomes at the molecular and cellular level.

BiotechDeep TechHardwareMedical Devices

Andrea(Co-founder & Chief Scientific Officer)Gerrit(Co-founder & Director of Product Management and Marketing)Hugo(CEO)Edmee(Chief Financial Officer)Hannah(HR Director)

Co-investorsLauxera Capital PartnersSoftBank Vision FundIrving InvestorsPura Vida InvestmentsT. Rowe Price

AdmitHub provides AI-powered success coaching and conversation tools for higher education institutions to improve student engagement, retention, and outcomes.

AI & Machine LearningEdTechHR TechArlington, US

Andrew Magliozzi(Founder)in

Co-investorsFundersClubMichelson 20MM FoundationNXT VenturesTechstarsAlly Bridge GroupFountain Healthcare Partners+3 more

HealthtechPlymouth, US

Dan Sachs(Director)Peter Crosby(Executive Officer, Director)inJason Hannonin

BoardManus Rogan(Director)Antoine Papiernik(Director)

Co-investorsFountain Healthcare PartnersSofinnova PartnersAlly Bridge GroupViking Global Investors

HealthtechFremont, US

Anton Clifford(Executive Officer)James Leech(Executive Officer)Christopher Gleason(Executive Officer)Kevin K. Sidow(Executive Officer, Director)

BoardJoshua Makower(Director)Shahzad Malik(Director)in

Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Vertex Ventures HC

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more

Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters.

BiotechHardwareHealthtechMedical DevicesAliso Viejo, US

Brian J. Cox(Manager)Rhonda Robb(Executive Officer, Director)Robert Rosenbluth(Director)

BoardDonald Milder(Director)Jonathan Root(Director)inPaul Lubock(Director)

Co-investorsUS Venture PartnersVensana Capital

Performation provides business intelligence, data analytics, and monitoring software and consulting for the healthcare sector, covering areas such as care registration, capacity planning, and real-world monitoring.

Data & InfrastructureDigital HealthHealthtechSaaS

Symeres provides pharmaceutical quality management systems, drug discovery and development services, and contract manufacturing support for biotech and pharma companies.

BiotechDeep TechEnterprise SoftwareHealthtechNetherlands, NL

Henning Steinhagen(Chief Executive Officer (CEO))Jurgen Berendsen(Chief Financial Officer (CFO))

Co-investorsKeensight Capital

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBifLightstone VenturesNew Enterprise Associates (NEA)Novartis Venture FundYsios CapitalOost NL